LUX-Lung 3: A Randomized, Open-Label, Phase III Study of Afatinib Versus Pemetrexed and Cisplatin as First-Line Treatment for Patients With Advanced Adenocarcinoma of the Lung Harboring EGFR-Activating Mutations

摘要

James C. Yang, MD, presented the LUX-Lung 3 study, which is a randomized, open-label, phase III trial of afatinib versus cisplatin and pemetrexed as first-line treatment for patients with advanced adenocarcinoma of the lung harboring mutations that activate the EGFR. Afatinib is an irreversible ErbB family blocker.Afatinib differs from the reversible EGFR tyrosine kinase inhibitors (TKIs) gefi-tinib and erlotinib in that after it enters the cell, it covalently binds to the cys-teine residue of EGFR. This provides long inhibition of EGFR. Afatinib also inhibits other ErbB family receptor heterodimers, such as human epidermal growth factor receptor (HER) 2, HER3, and HER4. Additionally, afatinib has in vitro activity against the EGFR-resistant T790M mutation.